Fig. 3

Prediction of chemotherapy response level in LUAD patients and cell lines validation. A Histogram of the percentage of patients in the high and low-risk groups who received chemotherapy only in the TCGA-LUAD set who responded to treatment. **P < 0.01. B Boxplots reflect the differences in the degree of response to chemotherapy drugs between patients in the high-risk and low-risk groups in the TCGA-LUAD training set. ****P < 0.0001. C GSEA analysis shows signaling pathways significantly enriched in patients in the high-risk groups in the TCGA-LUAD training set. D Risk scores and IC50s to Etoposide in A549 and NCI-H1299 cell lines. E-F An CCK-8 assay was used to evaluate the viability of A549 and NCI-H1299 cells under different concentrations of Etoposide (20, 40, 60, 80, 100, 120, 150, and 180 µM) for 24 h. GraphPad Prism was used to analyze and visualize the data from the LUAD cells viability assay and the IC50 of Etoposide. G The LUAD cells viability of NCI-H1299 vs. A549. *P < 0.05 and ****P < 0.0001. H, J Colony formation assay of NCI-H1299 (H) and A549 (J) cell lines was performed to detect the colony formation ability. I, K Quantitative analysis of colony formation formed by LUAD cells was performed using ImageJ, followed by GraphPad Prism visualization. *P < 0.05, and ****P < 0.0001 vs. control group